These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 19965844)
1. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. Kang HS; Kim JH; Phi JH; Kim YY; Kim JE; Wang KC; Cho BK; Kim SK J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):673-8. PubMed ID: 19965844 [TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633 [TBL] [Abstract][Full Text] [Related]
3. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675 [TBL] [Abstract][Full Text] [Related]
4. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Lin SY; Wang YY; Sheu WH Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636 [TBL] [Abstract][Full Text] [Related]
5. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959 [TBL] [Abstract][Full Text] [Related]
6. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Jain A; Nanchahal J; Troeberg L; Green P; Brennan F Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425 [TBL] [Abstract][Full Text] [Related]
7. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome. Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251 [TBL] [Abstract][Full Text] [Related]
9. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Distler O; Del Rosso A; Giacomelli R; Cipriani P; Conforti ML; Guiducci S; Gay RE; Michel BA; Brühlmann P; Müller-Ladner U; Gay S; Matucci-Cerinic M Arthritis Res; 2002; 4(6):R11. PubMed ID: 12453314 [TBL] [Abstract][Full Text] [Related]
10. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646 [TBL] [Abstract][Full Text] [Related]
11. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. Kim MH J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886 [TBL] [Abstract][Full Text] [Related]
12. Platelet-rich plasma increases matrix metalloproteinases in cultures of human synovial fibroblasts. Browning SR; Weiser AM; Woolf N; Golish SR; SanGiovanni TP; Scuderi GJ; Carballo C; Hanna LS J Bone Joint Surg Am; 2012 Dec; 94(23):e1721-7. PubMed ID: 23224392 [TBL] [Abstract][Full Text] [Related]
13. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Brattström D; Bergqvist M; Hesselius P; Larsson A; Lamberg K; Wernlund J; Brodin O; Wagenius G Lung Cancer; 2002 Jul; 37(1):57-63. PubMed ID: 12057868 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518. Crul M; Beerepoot LV; Stokvis E; Vermaat JS; Rosing H; Beijnen JH; Voest EE; Schellens JH Cancer Chemother Pharmacol; 2002 Dec; 50(6):473-8. PubMed ID: 12451474 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150 [TBL] [Abstract][Full Text] [Related]
16. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625 [TBL] [Abstract][Full Text] [Related]
17. Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation. Barron GA; Goua M; Wahle KWJ; Bermano G Oncol Rep; 2017 Sep; 38(3):1886-1894. PubMed ID: 28714000 [TBL] [Abstract][Full Text] [Related]